Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
This study aims to provide a comprehensive understanding of sotorasib's mechanisms of action and resistance in NSCLC patients.
KRAS P.G12C|Non Small Cell Lung Cancer
DRUG: Sotorasib 120Mg Tab
Tumor response assessment, To evaluate tumor response at 4 months and decipher relevant biomarkers associated with primary (progression within the first 4 months) and acquired resistance to sotorasib (progression after 4 months)., at 4 months after treatment start
This study aims to provide a comprehensive understanding of sotorasib's mechanisms of action and resistance in NSCLC patients.